VACCINES AGAINST CHLAMYDIA TRACHOMATIS

Team Members

Amanda Collar

Susan Core

Alexandria Linville (former)

We are using virus-like particles (VLPs) derived from small RNA bacteriophages as antigen-display platforms for Chlamydia trachomatis vaccines.  We identify antigens of interest that are important for Chlamydia trachomatis infection, display them on VLPs using a variety of molecular biology techniques, and then test them for their immunogenicity and ability to elicit antibodies that can block Chlamydia trachomatis infection. 

​

Publications

AL Collar, AC Linville, SB Core, CM Wheeler, WM Geisler, DS Peabody, B Chackerian, KM Frietze. 2020. Antibodies to variable domain 4 linear epitopes of the Chlamydia trachomatis major outer membrane protein are not associated with chlamydia resolution or reinfection in women. mSphere Sep 2020 5 (5) e00654-20

https://msphere.asm.org/content/5/5/e00654-20

​